Acne vulgaris is a common skin condition which is estimated to affect 80% of people at some point between 11 and 30 years of age. The condition ranges from mild to severe with latter more likely to cause scarring and psychological impact such as depression, loss of self esteem and in extreme cases, suicidal ideation. Acne is responsible for a significant number of yearly physician office visits and direct costs for treatments which range from OTC lotions to prescription based antibiotics/retinoids.
An acne vaccine targeting the main causative bacterium P.acnes could have wide utility if it prevents inflammatory outbreaks in individuals suffering from acne. Indeed, the major vaccine manufacturer Sanofi Pasteur has already announced interest in this concept (University of San Diego collaboration) confirming its potential attractiveness.
This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of acne vaccines (value/volume) to 2030 in the Western region. The product examines different uptake scenarios of the vaccine in severe and non-severe patient groups at different age range(s). Detailed coverage of latest acne epidemiology is included, also a focus on current treatment pathways, costs and the need for a novel vaccine approach. This product is an essential component of any new internal exercise assessing the potential of new acne vaccines.